The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Quizartinib granted approval in Japan for the treatment of patients with newly diagnosed AML with FLT3-ITD mutations
On May 25, 2023, quizartinib, an oral, highly potent and selective type II FLT3 inhibitor was approved by Japan’s Ministry of Health, Labour, and Welfare (MHLW) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with FLT3-internal tandem duplication (FLT3-ITD) mutations.1
This approval is for use in combination with standard cytarabine and anthracycline induction, standard cytarabine consolidation chemotherapy, and as maintenance monotherapy. Quizartinib is the first FLT3 inhibitor approved for newly diagnosed patients with AML in Japan, having received approval in 2019 as a monotherapy in the relapsed/refractory AML setting.1
This approval is based on the results from the randomized, double-blind, placebo-controlled, phase III QuANTUM-First trial (NCT02668653), which has been previously covered on the AML Hub. In this trial, the addition of quizartinib to standard cytarabine and anthracycline induction and standard cytarabine consolidation, and quizartinib maintenance monotherapy was associated with a 22.4% reduction in the risk of death when compared with standard chemotherapy alone (hazard ratio, 0.78; 95% confidence interval [CI], 0.62–0.98; p = 0.032).1 Median overall survival in the quizartinib arm (n = 268) was 31.9 months (95% CI, 21.0–NE) compared with 15.1 months (95% CI, 13.2–26.2) in the standard chemotherapy arm (n = 271).1 The most common adverse reactions in patients who received quizartinib were neutropenia (25.0%), thrombocytopenia (22.7%), nausea (20.6%), and electrocardiogram QT prolonged (19.3%), consistent with previous reports.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content